Professor Eric Bruckert
Disclosure details
Consulting/presentation: Amgen, Genfit, MSD, Sanofi-Regeneron, Aegerion, Ionis pharmaceuticals, Servier, Mylan, Novartis, Silence therapeutic, and AKCEA.Director of the Endocrinology-Metabolism Division and the Department of Prevention of Cardiovascular Disease at the Pitié-Salpêtrière University Hospital, Paris, France
Member of the Executive Committee of the Institute of Cardio-metabolism and Nutrition (ICAN)
Eric Bruckert is a clinician affiliated to Paris Sorbonne University, a full Professor of Endocrinology, and a cardiologist by training. He was President of the French Society of Atherosclerosis from 2015 to 2017, and is a member of the French Society of Endocrinology and the French Society of Cardiology. He has authored 7 books and more than 850 papers of which some 370 are in peer-reviewed journals. The main research interests of Prof Bruckert are focussed on dyslipidemia, familial hypercholesterolemia and prevention strategies for cardiovascular disease. He has been a principal investigator in more than 30 clinical trials with lipid lowering agents.
He served as a member of the Local Organizing Committee for the Congress of the European Atherosclerosis Society (EAS) held in Lyon in 2013, and is Co-Chair of the EAS recommendations for diagnosis and treatment of homozygous familial hypercholesterolemia. He has contributed to several Expert Consensus Panels organised by EAS.
